The Therapeutic Effect of Ozone and/or Prolotherapy on the Free Oxygen Radicals

biyomedikalozel5-1-24kapak

Selim KARABEKİRa
aDokuz Eylül University Faculty of Medicine, Department of Neurosurgery, İzmir, Türkiye

Karabekir S. The therapeutic effect of ozone and/or prolotherapy on the free oxygen radicals. In: Koçdor H, Pabuççuoğlu A, Zihnioğlu F, eds. Inflammation and in vitro Diagnostics. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.180-9.

Article Language: EN

ABSTRACT
Investigating the role of ozone therapy and prolotherapy, which are complementary medicine applications as current treatment approaches on free oxygen radicals is extremely significant in the neurosurgical clinic. Ozone (O3) is a gaseous nonradical molecule consisting of three oxygen atoms and is a colorless, pungent odorous molecule that is more unstable than oxygen. The basic logic of ozone therapy, which is one of the regenerative medicine technique, is the development of living tissues that will replace and repair damaged tissues. The other traditional medicine method called as prolotherapy, is to important for improve neurological system and also body health promotion, improve functional capacity of body and reduce pain. Prolotherapy is a medical injection treatment and the injected solution consists of natural sugar or salt water. The body perceives this solution as harmful and sends cells to the injection site that initiate the natural healing process. Prolotherapy injection mimics the natural tissue healing process via strengthening ligaments and tendon structures by stimulating the three phases of tissue healing, namely inflammation, proliferation and tissue regeneration.

Keywords: Free oxygen radicals; ozone therapy; prolotherapy

Referanslar

  1. Ozyalcin NS. Use of Ozone in Pain Deriving from Spine. Arslantaş A, Dalbayrak S, Şimşek S, Çağlı S, Kılınçer C, Coşar M, et al, eds. Minimally Invasive Spine Surgery: Current Aspects.2015. p.189-92. [Link]
  2. Kief H. Ozone and The Auto-homologous Immune Therapy in AIDS Patients [Link]
  3. Babacan A. Ozon, Ozonterapi ve Klinik Kullanımı. Turkiye Klinikleri J Med Sci. 2008;28(6 Suppl 1):245-7
  4. Dayanır H, Dayanır D, Babacan A. Ozon Tedavisi ve Enjeksiyonlardaki Yeri Ağrı ve Enjeksiyonlar. 1. Baskı. Ankara: Türkiye Klinikleri; 2019. p.118-22.
  5. Clavo B, Esparragón FR, Abreu DR, Sánchez GM, Llontop P, Aguiar BD, et al. Modulation of Oxidative Stress by Ozone Therapy in the Prevention and Treatment of Chemotherapy-Induced Toxicity: Review and Prospects. Antioxidants (Basel). 2019;8(12): 588. [Crossref]  [PubMed]  [PMC]
  6. Schwartz A, Sánchez GM. International Scientific Committee of Ozonetherapy (ISCO3).Ozone Therapy and Its Scientific Foundations. 2012. p.3-17.
  7. Herbert BS . The impact of telomeres and telomerase in cellular biology and medicine: it's not the end of the story. J Cell Mol Med. 2011;15(1):1-2. [Crossref]  [PubMed]  [PMC]
  8. Wiegman CH, Li F, Clarke CJ, Jazrawi E, Kirkham P, Barnes PJ, et al. A comprehensive analysis of oxidative stress in the ozone-induced lung inflammation mouse model. Clin Sci (Lond). 2014;126(6):425-40. [Crossref]  [PubMed]
  9. Mumby S, Chung KF, Adcock IM. Transcriptional Effects of Ozone and Impact on Airway Inflammation. Front Immunol. 2019;10:1610. [Crossref]  [PubMed]  [PMC]
  10. Hao K, Tang S, Xie H, Li X, He X. Application of ozone therapy in interventional medicine. J Interv Med. 2019;2(1):8-11. [Crossref]  [PubMed]  [PMC]
  11. Shinde SR, Apte S. A Systematic Review on Advancements in Drinking Water Disinfection Technologies: A Sustainable Development Perspective. Journal of Environmental Treatment Techniques. 2021;9(2):249-60. [Crossref]
  12. Bagchi K, Puri S. Free radicals and antioxidants in health and disease: A review. Mediterranean Health Journal. 1998; 4(2):350-60. [Crossref]
  13. Wojtunik-Kulesza KA, Oniszczuk A, Oniszczuk T, Waksmundzka-Hajnos M. The influence of common free radicals and antioxidants on development of Alzheimer's Disease. Biomedicine & Pharmacotherapy. 2016;78:39-49. [Crossref]  [PubMed]
  14. Jiang T, Sun Q, Chen S. Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson's disease and Alzheimer's disease. Progress in Neurobiology. 2016:147:1-19. [Crossref]  [PubMed]
  15. Bocci V, Zanardi I, Huijberts MSP, Travagli V. Diabetes and chronic oxidative stress. A perspective based on the possible usefulness of ozone therapy. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2011;5(1):45-9. [Crossref]  [PubMed]
  16. Elvis A, Ekta J. S. Ozone therapy: A clinical review. J Nat Sci Biol Med. 2011;2(1):66-70. [Crossref]  [PubMed]  [PMC]
  17. Shoemaker JM. Ozone Therapy - History, Physiology, Indications, Results. 2005. [Link]
  18. Noori-Zadeh A, Bakhtiyari S, Khooz R. Intra-articular ozone therapy efficiently attenuates pain in knee osteoarthritic subjects: A systematic review and meta-analysis. Complementary Therapies in Medicine. 2019;42:240-7. [Crossref]  [PubMed]
  19. Yalcin U. Paravertebral intramuscular ozone therapy in lumbar disc hernia: A comprehensive retrospective study. Journal of Back and Musculoskeletal Rehabilitation. 2021;34 (4):597-604. [Crossref]  [PubMed]
  20. MaslennikovOV.Ozone therapy in Practice, 2008. [Link]
  21. Gracer RI, Bocci V. Can the combination of localized "proliferative therapy" with "minor ozonated autohemotherapy" restore the natural healing process? Medical Hypotheses. 2005;65:752-9. [Crossref]  [PubMed]
  22. Krstičević M , Jerić M, Došenović S, Kadić AJ, Puljak L. Proliferative injection therapy for osteoarthritis: a systematic review. International Orthopaedics. 2017;41: 671-9. [Crossref]  [PubMed]
  23. Martínez-Sánchez G, Re L. Rectal administration and its application in ozonetherapy. Int J Ozone Therap 2012;11(1):41-9.
  24. Babcock P. Webster's Third International Dictionary. Springfield, MA: G&C Merriam Co; 1971.
  25. Goswami A. Prolotherapy. Journal of Pain & Palliative Care Pharmacotherapy. Taylor & Francis; 2012. [Crossref]  [PubMed]
  26. Hackett G, Hemwall GA, Montgomery GA. Ligament and tendon relaxation 1958 [Link]
  27. Hackett G. Joint stabilization: an experimental, histological study with comments on the clinical application in ligament proliferation. Am J Surg. 1955;89:968-73. [Crossref]  [PubMed]
  28. Hackett G. Back pain following trauma and disease prolotherapy. Mil Med. 1961;126:517-25. [Crossref]  [PubMed]
  29. Hackett GS, Ligament and tendon relaxation treated by prolotherapy. Oak Park, Illinois: Hemwall, GA; 1993. p.94-100.
  30. Hauser RA. A Retrospective Study on Hackett-Hemwall Dextrose Prolotherapy for Chronic Hip Pain Journal of Prolotherapy. 2009;1(2):76-88.
  31. Hauser RA, Maddela HS, Alderman D, Baehnisch G, Banner R, Blakemore PJ, et al. Journal of Prolotherapy International Medical Editorial Board Consensus Statement on the Use of Prolotherapy for Musculoskeletal Pain. Journal of Prolotherapy. 2012; 3(4):744-64.
  32. Reeves K. Prolotherapy: injection of growth factors or growth factor production stimulants to growth normal cell or tissue. In: Waldman SD, ed. Pain Management. Philadelphia: Elsevier; 2006. p.1106-27. [Crossref]
  33. Reeves KD, Hassanein K. Randomized, prospective, placebo-controlled double-blind study of dextrose prolotherapy for osteoarthritic thumb and finger (DIP, PIP, and Trapeziometacarpal) joints: evidence of clinical efficacy. J Altern Complem Med. 2000;6(4):311-20. [Crossref]  [PubMed]
  34. Jensen KT, Rabago DP, Best TM, Patterson JJ, Vanderby R Jr. Early inflammatory response of knee ligaments to prolotherapy in a rat model. J Orthop Res. 2008;26(6):816-23. [Crossref]  [PubMed]  [PMC]
  35. Kim SR, Stitik TP, Foye PM, Greenwald BD, Campagnolo DI. Critical review of prolotherapy for osteoarthritis, low back pain, and other musculoskeletal conditions: a physiatric perspective. Am J Phys Med Rehabil. 2004;83(5):379-89. [Crossref]  [PubMed]
  36. Kim S, Kim E, Kim S, et al. The effects of hyperosmolar dextrose and autologous serum injection in the experimental articular defect of rabbit. J Korean Acad Rehabil Med. 2006;30(2):173e178.hys Med Rehabil. 2004;83(5):379-89.
  37. Wee TC, Rui Neo EJ Leng Tan Y. Dextrose prolotherapy in knee osteoarthritis: A systematic review and meta-analysis. Journal of Clinical Orthopaedics and Trauma. 2021;19:108e117. [Crossref]  [PubMed]  [PMC]
  38. Di Paolo S, Gesualdo L, Ranieri E, Grandaliano G, Schena FP. High glucose concentration induces the overexpression of transforming growth factor-beta through the activation of a platelet-derived growth factor loop in human mesangial cells. Am J Pathol. 1996;149(6):2095-106.
  39. Okuda Y, Adrogue HJ, Nakajima T, et al. Increased production of PDGF by angiotensin and high glucose in human vascular endothelium. Life Sci. 1996;59(17):1455e1461. [Crossref]  [PubMed]
  40. Rabago David, Slattengren Andrew, Zgierska Aleksandra. Prolotherapy in Primary Care Practice Prim Care. 2010;37(1):65-80. [Crossref]  [PubMed]  [PMC]
  41. Hackett GS Pmeroy History and Basic Principles of Prolotherapy/Sclerotherapy: Local and referred pain, somatic and neurologycal, AOAS yayınları, Dallas, Texas,1979.
  42. Hackett GS, Hemwall GA, Montgomery GA. Ligament and tendon relaxation treated by prolotherapy. 5. Oak Park: Gustav A. Hemwall; 1993. [Link]
  43. Schultz L. A treatment for subluxation of the temporomandibular joint. JAMA 1937;190:1032-5. [Crossref]
  44. Cailliet R. Soft Tissue Pain and Disability. 3rd ed. Philadelphia, FA: Davis; 1998.
  45. Goswami A. Prolotherapy. J. Pain Palliat. Care Pharmacother. 2012;26:376-8. [Crossref]  [PubMed]
  46. Klein RG, Dorman TA, Johnson CE: Proliferant injections for low back pain: Histologic changes of injected ligaments and objective measurements of lumbar spine mobility before and after treatment. J Neurol Orthop Med Surg. 1989;10:141-4.
  47. Yelland MJ, Glasziou PP, Bogduk N, Schluter PJ. Prolotherapy injections, saline injections, and exercises for chronic low-back pain: a randomized trial. Spine. 2004;29(1):9-16. [Crossref]  [PubMed]
  48. Seltzer J, Bigby BG, Stulbarg M, Holtzman MJ, Nadel JA, Ueki IF, et al. O3-induced change in bronchial reactivity to methacholine and airway inflammation in humans. J Appl Physiol. 1986;60:1321-6. [Crossref]  [PubMed]
  49. Mudway IS, Kelly FJ. Ozone and the lung: a sensitive issue. Mol Aspects Med. 2000;21:1-48. [Crossref]  [PubMed]
  50. Edwards SG, Calandruccio JH: Autologous blood injections for refractory lateral epicondylitis. J Hand Surg (Am). 2003;28:272-8. [Crossref]  [PubMed]
  51. Dagenais S, Ogunseitan O, Haldeman S. Side effects and adverse events related to intraligamentous injection of sclerosing solutions (prolotherapy) for back and neck pain: A survey of practitioners. Arch Phys Med Rehabil. 2006;87(7):909-13. [Crossref]  [PubMed]
  52. Dagenais S. Intraligamentous injection of sclerosing solutions: prolotherapy for spine pain: a critical review of the literature. Spine J. 2005;5:310-28. [Crossref]  [PubMed]
  53. Yaman H, Akçay İ, Yıldız S. Prolotherapy: Practices, Experiences and Observations Concerning Adverse Effects of Physician in Turkey. Ulutas Med J. 2019;5(1):54-9. [Crossref]
  54. Rabago D, Slattengren A, Zgierska A. Prolotherapy in primary care practice.Prim Care. 2010;37(1):65-80. [Crossref]  [PubMed]  [PMC]
  55. Slattengren A, Zgierska A. Prolotherapy in primary care practice. Dextrose prolotherapy in knee osteoarthritis: A systematic review and meta-analysis Prim Care. 2010;37:65-80. [Crossref]  [PubMed]  [PMC]
  56. Shallenberger F. Prolozone - Regenerating Joints and Eliminating Pain. Journal of Prolotherapy. 2011;3(2):630-8.